GlobeNewswire Inc.··Kdventures AbOrganon Discontinues Second Forendos Drug Candidate, KDventures Faces Total Loss
Organon discontinues second Forendo drug candidate for PCOS, eliminating all programs from 2021 acquisition. KDventures writes off remaining contingent consideration entirely.
OGNpharmaceutical developmentdrug development discontinuation